Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciclesonide MDI for Symptomatic COVID-19
NCT04377711Phase 3Completed
- Sponsor
- Covis Pharma
- Start
- Jun 2020
- Primary completion
- Jan 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ciclesonide with Placebo (2 arms). Primary endpoint: Time to Alleviation of COVID-19-related Symptoms at Day 30. Started Jun 2020; status: completed.
02
Drugs
ciclesonide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04377711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04377711.